The pharmaceutical industry, a cornerstone of global healthcare, is constantly evolving, driven by innovation, strategic partnerships, and robust investor relations. In this dynamic landscape, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a prominent player known for its innovative biopharmaceuticals and extensive generics portfolio, is poised to engage with the investment community at two significant November conferences. These engagements offer a crucial opportunity for the company to articulate its strategic direction and financial health to a discerning audience.

Richard Francis, Teva’s President and CEO, is scheduled to present at these high-profile events, offering insights into the company’s performance and future vision. This direct interaction with investors is vital for maintaining transparency and confidence in the company’s trajectory amidst an increasingly competitive global market.

Upcoming Investor Conference Schedule

Teva has formally announced its participation in two key investor conferences, providing specific details for stakeholders interested in the company’s strategic updates:

  • UBS Global Healthcare Conference: Mr. Francis will deliver his presentation on Monday, November 10, 2025, commencing at 8:45 A.M. Eastern Time (ET). This conference is a significant platform for pharmaceutical leaders to discuss industry trends, financial performance, and future growth drivers within the global healthcare sector.
  • Jefferies London Healthcare Conference: The second engagement is set for Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET). This London-based event underscores Teva’s commitment to reaching a broad international investor base, reflecting the global nature of the pharmaceutical sector and its impact on healthcare destinations worldwide.

For those unable to attend in person, Teva ensures broad accessibility. A live webcast of the presentations will be available via Teva’s dedicated Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. Furthermore, an archived version of each webcast will be made accessible within 24 hours following the conclusion of the live discussions, allowing for flexible review by investors and interested parties worldwide.

Teva’s Enduring Legacy and Strategic Imperatives

With a history spanning over 120 years, Teva Pharmaceutical Industries Ltd. has consistently demonstrated a steadfast commitment to advancing health globally. The company’s dual strength, combining a world-class generics business with an innovative biopharmaceutical segment, positions it uniquely within the industry. From pioneering advancements in neuroscience and immunology to ensuring the global availability of complex generic medicines, biosimilars, and essential pharmacy brands, Teva’s mission is deeply rooted in addressing the evolving needs of patients. Its corporate philosophy,